Atrox

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Atrox

Property Description
Active ingredient Atorvastatin
Form Film-coated tablet
Pharmacological class Statin (HMG-CoA Reductase Inhibitor)
Common use Modifying blood lipid profile
Origin Synthetic compound

What Type of Medicine is Atrox?

Atrox is a synthetic, prescription-only medicine that contains the active ingredient Atorvastatin. It belongs to the class of medications known as statins, which are primarily used to manage blood lipid levels and is taken orally as a film-coated tablet. This drug entity is classified scientifically as an HMG-CoA reductase inhibitor, reflecting its precise pharmacological action. Unlike certain older analogues in the class, Atorvastatin is characterized by its high potency and extended duration of action. Atrox is a single-ingredient product designed for systemic administration, meaning its therapeutic effects are realized throughout the body after absorption. Understanding its classification defines its role as a component in cardiovascular health management, used for addressing chronic lipid imbalance.

Atorvastatin: Composition and General Purpose

The core of Atrox is the synthetic chemical entity Atorvastatin, typically formulated as Atorvastatin calcium within the solid oral matrix of the tablet. Atorvastatin is a synthetic compound and not naturally derived. The general purpose of Atrox is to reduce elevated cholesterol and lipoprotein concentrations in the blood. Atorvastatin achieves its effects by inhibiting cholesterol synthesis in the liver, leading to lower levels of “bad” cholesterol in the bloodstream.

This medication works by focusing on internal cholesterol synthesis. It blocks a critical enzyme required for producing cholesterol, thereby reducing the overall amount of cholesterol the body makes. The statin class is effective at lowering both total cholesterol and low-density lipoprotein (LDL) cholesterol. This consistent action provides a fundamental benefit in managing a patient's lipid profile, a key factor in prevention strategies.

Regulatory References

  1. HMG-CoA Reductase Inhibitors - NCBI Bookshelf

What side effects are possible with Atrox?

Possible Side Effects and Safety Information

The safety profile for Atrox (Atorvastatin) organizes potential adverse reactions according to both the affected body system and estimated frequency, strictly based on government regulatory documentation. Reactions are classified into categories such as Common, Uncommon, Rare, and Very Rare.

Key adverse reactions officially listed in regulatory documents involve the Musculoskeletal, Gastrointestinal, and Nervous Systems. Common reactions include headache, myalgia (muscle pain), arthralgia, and gastrointestinal disturbances (such as nausea, flatulence, and constipation). Laboratory observations like increased blood creatine kinase and abnormal liver function test results are also listed as common.

Serious adverse reactions, though Rare, are explicitly highlighted in the official labeling. These include rhabdomyolysis, a severe muscle condition that can lead to kidney issues, and reports of hepatic failure. Serious hypersensitivity reactions like angioneurotic oedema and severe skin reactions have also been documented. Some severe conditions, such as Immune-mediated necrotizing myopathy (IMNM), are listed as frequency not known.

Regulatory documents define specific safety constraints. The medicine is contraindicated for use in individuals with active liver disease or persistent, unexplained elevations in liver enzymes. It is also strictly contraindicated during pregnancy and lactation. The risk of serious muscle effects, such as myopathy, is noted to increase with higher doses and when co-administered with certain other medicines.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory documents for Atorvastatin (Atrox) confirm that no specific treatment or antidote is documented for overdosage, strictly limiting management to symptomatic and supportive measures instituted as required. Due to extensive plasma protein binding, regulatory information states that hemodialysis is not expected to significantly enhance drug clearance.

Overdosage is primarily defined by the risk of severe muscular and hepatic toxicity. Officially documented clinical manifestations include the onset of myopathy (muscle disease) and the finding of markedly elevated Creatine Kinase (CK) levels, often exceeding ten times the upper limit of normal. Severe, life-threatening outcomes listed in regulatory documents include rhabdomyolysis, which can lead to subsequent acute renal failure. Instances of serious hepatic injury, including jaundice and rare reports of fatal hepatic failure, have also been documented.

Regulators require patients to promptly report specific clinical signs to a healthcare professional. These include unexplained muscle pain, tenderness, or weakness, especially if accompanied by malaise or fever. Immediate medical help must also be sought for any signs of a severe allergic reaction (e.g., swelling of the face, difficulty breathing). Risk factors contributing to the severity of these outcomes include advanced age (> 65 years) and pre-existing renal or hepatic impairment. The official label mandates discontinuation of treatment if myopathy is diagnosed or suspected.

Therapeutic Uses of Atrox

What Atrox Treats: Main Uses and Benefits

Atrox is commonly used as a treatment option for managing chronic systemic lipid imbalances, focusing on elevated Low-Density Lipoprotein Cholesterol (LDL-C) and triglycerides. This medicine is utilized in instances where additional support is needed to address metabolic risk factors.

It plays a role in managing the risk of future acute symptomatic events, assisting with conditions like primary hypercholesterolemia, mixed dyslipidemia, and severe familial hypercholesterolemia. This preventative approach may assist with reducing the likelihood of severe, disruptive symptomatic episodes, such as non-fatal myocardial infarction and stroke, particularly in high-risk patients with comorbidities like Type 2 diabetes.

“This therapeutic support is commonly used to help with the long-term control of underlying vascular risk factors, which supports general well-being and continuity of daily functioning.”

Atrox is also applied across domains where additional symptomatic support is needed to address chronic, measurable risk factors.


Quick Fact: Support for Asymptomatic Vascular Risk Factors This medication is primarily relevant for managing silent, measurable risk factors, where its supportive action may assist with maintaining functional stability.

Regulatory References

  1. NIH StatPearls overview on Atorvastatin

Eligibility and Restrictions for Use

Who can and cannot use Atrox? (Atorvastatin)

This section outlines the official population eligibility and non-eligibility rules for using Atrox, based strictly on government-approved regulatory documents.


Absolute Contraindications (Must Not Use)

Atrox is contraindicated (must not be used) in patients with specific conditions, as defined in regulatory labeling:

  • Active Liver Disease: This includes unexplained persistent elevations of liver enzymes (serum transaminases) exceeding three times the upper limit of normal.
  • Hypersensitivity: Known allergy to the active substance, Atorvastatin, or any components of the tablet.
  • Reproductive Status: The medicine is contraindicated during pregnancy and breastfeeding. Women who may become pregnant must use effective contraception during treatment.

Eligibility by Age and Condition

Population Group Regulatory Eligibility Status
Adults Allowed under standard labeled conditions.
Pediatric Use Allowed for children and adolescents aged 10 years and older for specific conditions. Not established for those under 10 years.
Renal Impairment Allowed. No dose adjustment is required based on kidney function alone.
History of Liver Disease Use with caution and monitoring is required due to risk factors.

Regulatory documents define eligibility by establishing prohibitions, setting minimum age thresholds, and requiring special caution in specific patient groups.

What should I know about interactions with other medicines?

Atrox Interactions with other medicines and products

Official regulatory documentation identifies clinically significant interactions involving products that affect the metabolism of Atrox, as well as specific drugs that carry a risk of additive effects. These interactions are primarily categorized by their pharmacokinetic mechanism, which results in altered exposure of either Atrox or the co-administered medication.

Interacting Medicinal Product Categories

Interaction Type Examples of Affected Categories
Metabolic Enzyme Modifiers Strong CYP3A4 inhibitors; Strong CYP3A4 inducers.
Anticoagulants Warfarin and other oral blood thinners.
QTc-Prolonging Agents Certain antiarrhythmics and antidepressants.

Co-administration with strong CYP3A4 inhibitors is predicted to significantly increase the systemic concentration of Atrox, which may require specific monitoring or dose limitations. Conversely, concurrent use with strong CYP3A4 inducers is expected to decrease Atrox exposure, potentially leading to reduced effectiveness.

Regulatory labeling specifically cautions that Atrox may enhance the effect of anticoagulants like warfarin, necessitating closer monitoring of clotting factors. Additionally, because Atrox is associated with a risk of QTc interval prolongation, its use with other medications that share this effect is officially restricted due to the potential for additive cardiac effects. Drug interaction information also notes that the absorption of Atrox may be reduced when taken with dairy products.

Mechanism of Action

Hemocoagulase Atrox, an enzyme derived from Bothrops atrox, acts within the coagulation cascade through distinct mechanistic domains, altering pathway activity within the hemostatic system.

Direct Fibrin Formation by Thrombin Mimicry

This domain involves Atrox directly cleaving the soluble plasma protein fibrinogen to form insoluble fibrin monomers. By bypassing upstream coagulation factors and acting as a thrombin-like enzyme, this mechanism rapidly initiates the formation of a stable, three-dimensional fibrin mesh that results in the formation of a localized fibrin mesh.


️ Activation of the Coagulation Cascade

Atrox also engages mechanisms that amplify the natural clotting sequence by directly activating Factor X (FX) into its active form, Factor Xa (FXa). This modifies early molecular steps within the coagulation cascade, leading to enhanced downstream generation of thrombin and increased localized procoagulant activity, contributing to the localized and accelerated formation of a fibrin clot.


Targeted Fibrinogen Consumption (Defibrinogenation)

A third domain involves the enzyme's ability to cleave fibrinogen into non-clottable fragments. This process reduces the circulating concentration of soluble fibrinogen, and elicits downstream physiological changes resulting from fibrinogen cleavage.

Dosage and Administration Information

Official Administration Guidelines

Atrox, containing the active ingredient Atorvastatin, is a film-coated tablet intended for oral administration. The medicine is characterized by specific parameters that define its standard consumption.


Feature Official Instruction
Route of Administration Oral administration only, as a solid tablet.
Dosing Schedule The standard adult starting dose is 10 mg or 20 mg once daily, with a maximum dose of 80 mg once daily.
Frequency and Timing The tablet must be taken as a single dose once daily. It may be taken at any time of the day, with or without food.
Age-Group Rules For pediatric patients (10 to 17 years of age) with Heterozygous Familial Hypercholesterolemia (HeFH), the recommended starting dose is 10 mg once daily, with a maximum dose of 20 mg once daily.
Missed Dose Rule If a scheduled dose is missed, the standard procedure is not to take the missed dose and to resume the regular once-daily schedule with the next dose.

Special Procedural Constraints

The dosage must be limited when Atrox is co-administered with certain medications. For example, the dose should not exceed 10 mg daily when taken with Cyclosporine, or 20 mg daily when taken with Clarithromycin or specific HIV/Hepatitis C protease inhibitor combinations. Therapy is typically long-term and chronic, and dose adjustments are typically made at intervals of four weeks or more based on lipid level assessment.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Atrox

Evidence for Managing Severe Lipid Imbalances

Research regarding the use of Atrox (Atorvastatin) in clinical situations characterized by high levels of cholesterol and other fats (lipids) in the blood primarily relies on short-term to intermediate-term Randomized Controlled Trials (RCTs) and systematic reviews. These studies were designed to track and measure changes in blood biomarkers such as Low-Density Lipoprotein Cholesterol (LDL-C), Total Cholesterol, and Triglycerides over defined time intervals. Populations studied included adults with various forms of hypercholesterolemia and specific pediatric groups.

Studies described patterns of changes in measured lipid markers, such as a shift toward lower LDL-C and Total Cholesterol in the observed populations receiving Atorvastatin. Comparative studies examined measurements of lipid markers when Atorvastatin was administered alongside other lipid-altering therapies or placebo conditions. However, research does not determine whether an individual will respond similarly, as the results apply only to the specific conditions and populations studied.

Evidence for Preventing First-Time Cardiovascular Events

The evidence base for research on first-time major event rates in clinical situations involving Atrox comes from large-scale, long-term outcomes-based RCTs. These research efforts focused on adults who were at high risk due to multiple factors—such as high blood pressure or having Type 2 diabetes—but who had not yet been diagnosed with established heart disease. These studies monitored the incidence of first-time Major Adverse Cardiovascular Events (MACE) over several years of observation.

Studies examined the rate of first-time MACE in the groups receiving Atorvastatin compared to the placebo groups over the observation period, noting the pattern of difference in occurrences. Studies monitored outcomes related to systemic or functional imbalance, such as the number of non-fatal strokes or heart attacks that were monitored. Long-term effects are not fully established for all possible subgroups, and evidence quality varies across studies when examining secondary outcomes.

What is Still Uncertain About the Research for Atrox

Certainty remains low regarding the direct comparative evaluation against all other members of the statin class in long-term head-to-head outcomes trials. Furthermore, evidence derived from settings with varying symptom burdens, such as the full spectrum of high-risk patients outside the narrowly defined trial protocols, appears to be limited, meaning the study results reflect the specific trial environment.

Frequently Asked Questions (FAQ)

Common questions about Atrox (FAQ)

Q: Does Atrox stay in your system for a long time?

A: Official product information, based on pharmacokinetic studies, indicates that Atorvastatin and its active breakdown products have an elimination half-life of approximately 20 to 30 hours. This information helps determine the necessary frequency of administration, which is typically once daily.

Q: Are there common long-term side effects associated with Atrox use?

A: Regulatory documents list side effects by their frequency (such as common, uncommon, or rare) and affected body system. Certain reactions, including muscle symptoms or changes in liver enzyme levels, are monitored throughout the chronic use of the medicine. Official regulatory documents typically list side effects based on frequency and body system, and do not define a separate category labeled 'long-term side effects.'

Q: Can Atrox be used by older adults?

A: Yes, official regulatory guidance permits the use of Atrox in the geriatric population. Official labeling notes that in individuals aged 65 years and older, a slightly increased risk for certain side effects, such as muscle pain or weakness, has been observed in studies.

Q: Do you need special monitoring while using Atrox?

A: Official regulatory guidance recommends that liver enzyme tests be considered before starting Atrox therapy and periodically during treatment. This monitoring is required because of the known risk of effects on the liver, which is why the medicine is contraindicated in patients with active liver disease.

Q: Is Atrox known to cause any skin reactions or rashes?

A: Official product labeling lists rare, serious skin reactions. These documented severe reactions include blistering or peeling skin conditions, and hypersensitivity reactions such as angioneurotic oedema (swelling beneath the skin).

Q: What does the FDA label say about the long-term safety of Atrox?

A: The official FDA label details the known safety profile established during clinical trials and post-marketing monitoring. The medicine is prescribed for long-term chronic use for its approved purpose. The label provides comprehensive information on adverse reactions, organized by frequency and body system.

Q: Are there any specific lab tests required before starting Atrox?

A: Official regulatory guidance states that liver enzyme tests should be considered before initiating therapy. This testing is officially recommended before starting treatment, due to the risk of hepatic dysfunction associated with the medicine.

Q: Why are there specific instructions about taking Atrox with or without food?

A: Official pharmacokinetic studies, which track how the drug moves through the body, show that food consumption does not significantly change the amount of Atorvastatin absorbed into the bloodstream. This finding allows the medicine to be taken at any time of day, with or without food, as officially advised.

Q: How quickly can a person expect Atrox to start working?

A: Clinical study data indicates that significant changes in blood lipid markers (such as cholesterol) are typically observed relatively quickly, usually within two weeks of starting the therapy. Clinical studies indicate that maximum reduction in these measured markers is typically observed within four weeks of starting therapy.

Q: Can Atrox cause feelings of fatigue or tiredness?

A: The official product labeling lists fatigue as an uncommon adverse reaction.

Q: Are there any specific lifestyle changes that are often mentioned alongside taking Atrox?

A: Official guidance from regulatory bodies states that the medicine should be used along with important lifestyle modifications. These include a diet, weight management, and exercise program, as officially described in the guidance for cardiovascular health management.

Q: Does Atrox have any warnings about driving or operating machinery?

A: Official product information states that the medicine has a negligible influence on the ability to drive or operate machinery. The official guidance states that individuals should be vigilant for any side effects, such as dizziness, that could potentially impair their ability.

Q: Is Atrox known to cause weight changes?

A: Weight gain or loss is not listed as a common or specific adverse reaction in regulatory documents. The medicine is intended to be used in conjunction with lifestyle management efforts, which often includes managing diet and weight.

Q: Can Atrox affect a person's mood or emotional state?

A: Post-marketing surveillance, which tracks side effects reported after a drug is widely available, includes reports of effects such as depression, sleep disturbances, or nightmares. These events are reported in a limited number of individuals.

Q: Is Atrox a controlled substance?

A: Official sources confirm that Atrox, which contains the active ingredient Atorvastatin, is not classified as a federally controlled substance under the Controlled Substances Act.

Q: Is it safe to drink alcohol while taking Atrox?

A: The official product label advises caution for patients who consume substantial quantities of alcohol, as this is linked to an increased risk of liver injury.

Q: Does Atrox cause dependence or withdrawal issues?

A: Official regulatory information does not classify Atrox as a substance that causes dependence. Furthermore, no specific withdrawal symptoms are officially listed as occurring when the medicine is stopped.

Q: Can Atrox be crushed or split if a person has trouble swallowing?

A: The medicine is supplied as a film-coated tablet for oral administration. Official instructions for the film-coated tablet do not include guidance for crushing or splitting it.

Q: Does Atrox interact with grapefruit or grapefruit juice?

A: Official labeling specifically warns that consuming large quantities of grapefruit juice should be avoided while taking Atrox. This is due to the potential for increased systemic exposure to the drug.

Q: Are there generic versions of Atrox available yet?

A: Yes. The active ingredient in Atrox, Atorvastatin, is widely available in generic formulations. The FDA requires that all approved generic products be therapeutically equivalent to the brand-name product, meaning they contain the identical active ingredient.

Q: Does Atrox affect fertility in men or women?

A: Official regulatory documents have indicated that there is no clear evidence suggesting that taking the active ingredient, Atorvastatin, reduces fertility in either men or women.

Q: What is the difference between the brand name and the generic version of Atrox?

A: The brand name and the generic version (atorvastatin) are required to contain the identical active ingredient in the same dose. The difference is primarily in non-active components, but the FDA requires the generic to be therapeutically equivalent to the brand-name product.

Q: Can Atrox be used for conditions not listed on the label?

A: The medicine is only officially approved and regulated for use in the specific conditions described in the 'Indications and Usage' section of the regulatory documents. Use outside of these specific, approved indications is not supported by the official label.

How should Atrox be stored and disposed of?

How to Store and Dispose of Atrox?

Storing Atrox (Atorvastatin) strictly according to regulatory labeling is essential for maintaining product stability. The medicine must be kept at controlled room temperature, typically 20 C to 25 C (68 F to 77 F), and stored away from environmental factors that can compromise the tablet, such as freezing, excessive moisture, heat, and direct light.

Storage Restriction Official Requirement
Temperature Do not freeze; store below 30 C (varies by region).
Child Safety Must be kept out of the sight and reach of children.

The official shelf-life of Atrox is determined by the expiry date on the original container. For disposal, unused or expired tablets must not be discarded in household trash or flushed down the toilet. Instead, disposal must strictly follow local pharmaceutical waste regulations as directed by a healthcare professional or pharmacist.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Atrox found in:

A-Z Index: